title: Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
abstract: Hodgkin's disease (HD) is the most common non-acquired immunodeficiency syndrome (AIDS)-defining malignancy in human immunodeficiency virus (HIV)-infected patients. We analysed the outcome of patients with HIV-associated HD (HIV-HD) with respect to the use and efficacy of highly active antiretroviral therapy (HAART) and other prognostic factors. To evaluate the effects of several variables on overall survival (OS), Kaplan-Meier statistics and extended Cox regression analysis were performed. Response to HAART was used as a time-dependent variable and was defined as an increase of >0.1 x 10(9) CD4 cells/l and/or at least one viral load <500 copies/ml during the first 2 years following diagnosis of HIV-HD. Fifty-seven patients with HIV-HD diagnosed between 1990 and 2002 were included in the study. In the Cox model, the only factors independently associated with OS were HAART response [relative hazard (RH) 0.19; 95% confidence interval (CI) 0.06-0.60], complete remission (RH 0.30, 95% CI 0.13-0.72), and age <or=45 years (RH 0.23; 95% CI 0.09-0.60). Median survival time in patients without HAART response was 18.6 months, whereas the median survival time in patients with HAART response was not reached (89% OS at 24 months). In this cohort, a significant improvement in survival was found in patients with HIV-HD who responded to HAART.
authors.affiliation: II. Department of Internal Medicine, University Hospital of Kiel, Kiel, Germany. c.hoffmann@med2.uni-kiel.de
authors.forename: Christian
authors.initials: C
authors.lastname: Hoffmann
authors.forename: Kai Uwe
authors.initials: KU
authors.lastname: Chow
authors.forename: Eva
authors.initials: E
authors.lastname: Wolf
authors.forename: Gerd
authors.initials: G
authors.lastname: Faetkenheuer
authors.forename: Hans-Juergen
authors.initials: HJ
authors.lastname: Stellbrink
authors.forename: Jan
authors.initials: J
authors.lastname: van Lunzen
authors.forename: Hans
authors.initials: H
authors.lastname: Jaeger
authors.forename: Albrecht
authors.initials: A
authors.lastname: Stoehr
authors.forename: Andreas
authors.initials: A
authors.lastname: Plettenberg
authors.forename: Jan-Christian
authors.initials: JC
authors.lastname: Wasmuth
authors.forename: Juergen
authors.initials: J
authors.lastname: Rockstroh
authors.forename: Franz
authors.initials: F
authors.lastname: Mosthaf
authors.forename: Heinz-August
authors.initials: HA
authors.lastname: Horst
authors.forename: Hans-Reinhard
authors.initials: HR
authors.lastname: Brodt
mesh_terms: D000328:Adult; D000367:Age Factors; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality*; D015497:HIV-1; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012044:Regression Analysis; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents